医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NEWS > Home > > 疾病 > AIDS >

Register now: Civil Society Shaping Public Health – A Global AHF Dialog

2022年10月04日 AM05:00
このエントリーをはてなブックマークに追加


 

NUSA DUA, Indonesia

The Civil 20 (C20) Summit 2022 starts tomorrow in Indonesia, where AHF will host an exhibition booth and interactive in-person and virtual C20 Side Event – a Global Public Health Convention for the 21st Century. We invite you to register and join a panel of experts in a discussion on why the leaders of the Group of 20 (G20) must develop a comprehensive public health framework that promotes cooperation, transparency, and accountability among countries to respond to current and future health emergencies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005912/en/

In under a decade, the world has seen widescale outbreaks of infectious diseases of international concern, such as Ebola, Zika, COVID-19, and monkeypox. These outbreaks are occurring while long-running epidemics remain unresolved and underfunded, including AIDS, TB, and malaria, the re-emergence of polio and measles, and a resurgence of sexually transmitted diseases, such as syphilis.

“This C20 Side Event will allow us to hear from leading global public health thinkers about why infectious diseases need global solutions, which the G20 must urgently address to redefine and restructure public health,” said AHF Director of Global Advocacy & Policy Guillermina Alaniz. “If countries refuse to cooperate for the sake of global health, we are doomed to continue repeating the same mistakes that cause an untold number of avoidable deaths. We’re in survival mode as a global community – the time has come to redefine fundamental assumptions about multilateralism, international cooperation, and public health overall.”

Side Event panelists will also identify critical roles civil society needs to fill within a new public health framework and develop a consensus on core principles that C20 advocates can strongly recommend to G20 leaders as the basis for a new Global Public Health Convention.

“Crises like the COVID-19 pandemic have also shown the harmful health inequities that exist between wealthy and resource-constrained countries in access to lifesaving vaccines, diagnostics, treatments, and technologies,” said Deepak Dhungel, Advocacy & Marketing Manager for AHF’s Asia Bureau. “The G20 must immediately develop a comprehensive public health framework that promotes cooperation, transparency, and accountability globally – which is the only way to protect the world from widespread illness, loss of life, and economic decline. Global challenges demand collective global action.”

AHF also participated in the C20 Health Working Group sessions earlier this year that resulted in recommended priority issues for the G20, including addressing global health architecture, expanding access to all health and COVID-19 commodities, universal health coverage, and strengthening the public health ecosystem.

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 1.6 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005912/en/

CONTACT

US MEDIA CONTACT:

Ged Kenslea, Senior Director, Communications, AHF

+1.323.308.1833 work; +1.323.791.5526 mobile

gedk@aidshealth.org

Denys Nazarov, Senior Director of Media Relations, AHF

+1 323.308.1829

denys.nazarov@ahf.org

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Exscientia首次获得CTA核准,将启动EXS-21546治疗晚期实体瘤患者的1/2期IGNITE-AI试验
  • エクセンシア、進行性固形がん患者を対象としたEXS-21546の第1/2相試験IGNITE-AI開始のCTA承認を初めて取得
  • NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor’s TikTok Store in China and Expands Online Marketing in the U.S. and China
  • Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy
  • Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug